A new software algorithm decides which patients are most likely to become infected with the virus. But this is not like other risk calculators, some experts say. Source: NYT > Business – Gina Kolata
Someday, an Arm Implant May Prevent H.I.V. Infection for a Year
In preliminary tests, a matchstick-size rod containing a new drug offered promise as a shield against the virus. But a large clinical trial must still be done. Source: NYT > Business – Donald G. McNeil Jr.
Drug Companies Are Focusing on the Poor After Decades of Ignoring Them
The pharmaceutical industry once sued to keep AIDS drugs from dying Africans. Now companies boast of their efforts to get medicines to the developing world. Source: NYT > Business – Donald G. McNeil Jr.
Global Health: Gilead Will Donate Truvada to U.S. for H.I.V. Prevention
The manufacturer will provide enough of the drug to supply 200,000 patients annually for more than a decade. Critics said it would not be enough to end the AIDS epidemic and questioned the company’s motives. Source: NYT > Business – DONALD G. McNEIL Jr.
Trump’s Proposed Budget Undermines His H.I.V. Plan, Experts Say
Strategies abound to end the AIDS epidemic, but expense — mostly for drugs costing up to $50,000 a year — is the inevitable obstacle. Source: NYT > Business – DONALD G. McNEIL Jr.
An H.I.V. Cure: Answers to 4 Key Questions
Translating the latest success against the AIDS virus into a practical treatment will take years — if it happens at all. Here are answers to some of the most pressing questions raised by the news. Source: NYT > Business – APOORVA MANDAVILLI